Search Within

Meghan E Salcedo

Formats
  1. Meeting Abstract (11)
  2. Journal Article (5)
  3. Research Letter (3)
  4. Correspondence (2)
Groups
  1. Center for Hematologic Malignancies (21)
  2. Department of Medicine (21)
  3. Hematologic Malignancies Research (21)
  4. Hematologic Malignancies, Division of (21)
  5. Myeloma (21)
  6. Sloan Kettering Institute Postdocs (19)

More Groups

People
  1. Alexander Lesokhin (21)
  2. Hani Hassoun (19)
  3. Malin Hultcrantz (19)
  4. Neha Korde (19)
  5. Sham Mailankody (19)
  6. Carl Landgren (16)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (4)
  4. 2021 (4)
  5. 2020 (4)
  6. 2019 (4)

More Years

Publications
  1. Blood (9)
  2. Journal of Clinical Oncology (2)
  3. Leukemia and Lymphoma (2)
  4. American Journal of Hematology (1)
  5. Blood Advances (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (10)
  2. American Society of Clinical Oncology (2)
  3. Elsevier Inc. (2)
  4. Taylor & Francis Group (2)
  5. American Association for Cancer Research (1)
  6. American Medical Association (1)

More Publishers

Results (21)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Research Letter

    Hultcrantz, M.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; Lahoud, O. B.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: A prospective observational cohort study
    Journal Article

    Korde, N.; Tavitian, E.; Mastey, D.; Lengfellner, J.; Hevroni, G.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; more...
    eClinicalMedicine (2023)

    Fulltext@MSK | Save
  • A phase 2 trial of colesevelam for lenalidomide-associated diarrhea
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets
    Journal Article

    Shah, U. A.; Maclachlan, K. H.; Derkach, A.; Salcedo, M.; Barnett, K.; Caple, J.; Blaslov, J.; Tran, L.; Ciardiello, A.; Burge, M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
    Correspondence

    Mailankody, S.; Salcedo, M.; Tavitian, E.; Burge, M.; Korde, N.; Hassoun, H.; Lesokhin, A.; Lahoud, O.; Smith, E.; Hultcrantz, M.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients
    Meeting Abstract

    Hevroni, G.; Mastey, D.; Tavitian, E.; Derkach, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Journal Article

    Eveillard, M.; Korde, N.; Ciardiello, A.; Diamond, B.; Lesokhin, A.; Mailankody, S.; Smith, E.; Hassoun, H.; Hultcrantz, M.; Shah, U.; more...
    Clinica Chimica Acta (2021)

    Fulltext@MSK | Save